Christiaan Engstrom, MBA – President
Christiaan Engstrom draws on 15-plus years of experience in marketing, operations and management across life sciences, healthcare and manufacturing industries. Since joining the company in March 2014, the organization has reinvested record growth into its core operations, with the goal of earning a trusted global leader position in biopharmaceutical development and manufacturing.
Prior to accepting his role at C3, Mr. Engstrom was the Chief Operating Officer for a multi-specialty group of clinics in the greater Minneapolis-St. Paul area. Under his leadership, the team improved patient experience through streamlined operations, resulting in exponential growth over a three-year period. The team successfully delivered against its goal for acquisition in January 2014.
Mr. Engstrom received both his undergraduate and master’s degrees from the University of Minnesota’s Carlson School of Management. He is a Lean Process Improvement leader and his voice of customer, process improvement and quality experiences continue to guide aggressive growth strategies at C3.
Teresa Markoe, M.S. – VP, Finance and Human Resources
Teresa Markoe joined C3 in 2015 as an accountant. She was quickly promoted to Director of Accounting, then VP of Finance & HR. She has continuously improved C3's financial fundamentals and oversees the building of C3's greatest asset - its people.
Ms. Markoe went to the University of St. Thomas where she earned her Bachelor of Science and Master of Science in Accounting. Prior to coming to C3, she was working in public accounting at Ernst & Young and moved to industry working at Target Corporation.
Rebecca Thompson, Ph.D. – VP, Quality
Dr. Rebecca Thompson returned to Cell Culture Company in November of 2015 as Quality Manager and took on the role of Vice President of Quality in Nov of 2017. She oversees quality functions related to GxP compliance, analytical testing , and customer needs.
Prior to joining C3, Dr. Thompson was the Technical Supervisor of Cellular Immunology for Pharmasan Labs, a CLIA-certified laboratory. Rebecca earned her Ph.D. in Biomedical Sciences from the University of Toledo Health Science Campus and her B.S. in Pharmaceutical Sciences from the University of Toledo.
Scott Waniger – VP, Bioprocessing
With 29+ years of extensive experience in mammalian cell culture manufacturing, Scott has been a key player in C3’s growth and development. His broad scope of knowledge in operations, management and regulatory needs compliments his hands on experience.
Scott has overseen the expansion of 2650 + unique cell lines, producing monoclonal antibody, recombinant proteins, whole cell pellets, cellular extracts, and conditioned media from RUO to GMP applicationsHe has been fundamental in raising awareness and educating the life sciences industry on the benefits of perfusion based mammalian expression bioreactor systems. Scott has been with C3 since 1988.
Curt Gleiter – VP, Technical Services
Curt is the Vice President of the Instruments Division where he oversees the instrument and cultureware production teams as well as the technical and customer support teams. He supports direct customers and international distributors in protein production, Quality System Regulation-compliant operations, Installation and Operation Qualification (IOQ), and annual contracts. Curt has been with C3 since 1993.
Kyle Biesecker, PhD – Director, Business Development
Dr. Kyle Biesecker oversees business and corporate development activities at C3. He has 3+ years of experience in developing market entry, sales, and business strategies for medtech companies, as well as over 7 years of laboratory experience in physiology and molecular techniques. Dr. Biesecker received his Ph.D. in Neuroscience from the University of Minnesota and his B.S. in Biology from St. Olaf College.
Emily Wozniak, PhD – Director, Marketing
Dr. Emily Wozniak is responsible for overseeing C3’s marketing efforts, including market strategy and technical content generation. Dr. Wozniak has 3+ years experience in designing market strategy for various biotech and medtech companies. She received her PhD in Neuroscience from the University of Minnesota and has over 10 years of laboratory experience in therapeutic discovery using genetic, cellular, and molecular techniques.